Activity of ulifloxacin against clinical hospital isolates

Infezioni in Medicina

Volumn 15, Issue 3, 2007, Pages 169-173

  Gemignani, Giulia ^a   Tascini, Carlo ^a   Leonildi, Alessandro ^a   Piaggesi, Alberto ^a   Menichetti, Francesco ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Ciprofloxacin; Clinical isolate; Levofloxacin; Moxifloxacin; Ulifloxacin

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; ULIFLOXACIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG SENSITIVITY; GRAM POSITIVE BACTERIUM; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; NONHUMAN;

FLUOROQUINOLONES; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PIPERAZINES; QUINOLONES;

EID: 35948997368     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Keam S.J., Perry C.M. Prulifloxacin. Drugs 64, 2221-2234, 2004.
2. Yoshida T., Mitsuhashi S. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob. Agents Chemother. 37, 793-800, 1993.
3. Montanari M.P., Mingoia M., Varaldo P.E. In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolate. Antimicrob. Agents Chemother. 45, 3616-3622, 2001.
4. Roveta S., Schito A.M., Marchese A., Schito G.C. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroqionolone, in the eradication of serious infections caused by P. aeruginosa. Int. J. Antimicrob. Agents 26, 366-372, 2005.
5. Piddock L.J.V. New quinolones and Gram positive bacteria. Antimicrob. Agents Chemother. 38, 163-169, 1994.
6. Hooper D.C. New uses for new and old quinolones and the challenge of resistance. Clin. Infect. Dis. 30, 243-254, 2000.
7. th ed. Americ an Sociaty for Microbiology, Washington DC.
8. Montanari M.P., Ferrante L., Tili E., Cochetti I., Rossi V., Varaldo P.E. Interpretative criteria for disk diffusion susceptibility testing of ulifloxacin, the active metabolite of prulifloxacin. J. Chemother. 17, 138-42, 2005.
9. Noviello S., Ianniello F., Leone S., Esposito S. In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens. Infez. Med. 14, 24-28, 2006.
10. Abe N., Komatsu M., Iwasaki M., Agasaka Y., Fukuda S., Matsuo S., Shimakawa K. In vitro activity of antimicrobial agents against clinical isolates of P. aeruginosa. Jpn. J. Antibiot. 58, 445-451, 2005.
11. Concia E., Allegranzi B., Ciottoli G.B., Orticelli G., Marchetti M., Dionisio P. Penetration of orally administered prulifloxacin into human lung tissue. Clin. Pharmacokinet. 44, 1287-1294, 2005.
12. Tascini C., Piaggesi A., Gemignani C., Palumbo F., Leonildi A., Tedeschi A., Lambelet P., Lucarini A., Menichetti F. Clinical and microbiological efficacy of Colistin therapy alone or in combination as treatment for multidrug resistant P. aeruginosa diabetic foot infections with or without osteomyelitis. J. Chemother 18, 72-75, 2006.